High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis-Reference-Cited by-同舟云学术

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis

Published:2022-09-30 Issue:10 Volume:6 Page:e784
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Gagelmann Nico,Salit Rachel B.,Schroeder Thomas,Badbaran Anita,Rautenberg Christina,Panagiota Victoria,Wolschke Christine,Thol Felicitas,Cassinat Bruno,Robin Marie,Heuser Michael,Reinhardt Hans Christian,Scott Bart L.,Kröger Nicolaus

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference36 articles.

1. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.;Rumi;Blood,2017

2. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.;Passamonti;Blood,2014

3. Fedratinib in myelofibrosis.;Mullally;Blood Adv,2020

4. Novel therapies in myeloproliferative neoplasms: beyond JAK inhibitor monotherapy.;Lee;J Immunother Precis Oncol,2021

5. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.;Kröger;Leukemia,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of allogeneic stem cell transplantation in myelofibrosis;memo - Magazine of European Medical Oncology;2024-08-12

2. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation;Transplantation and Cellular Therapy;2024-08

3. Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation;Bone Marrow Transplantation;2024-05-21

4. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation;American Journal of Hematology;2024-05-14

5. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis;American Journal of Hematology;2024-02-15